RT Journal Article
SR Electronic
T1 Early alveolar epithelial cell necrosis is a potential driver of COVID-19-induced acute respiratory distress syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.23.22269723
DO 10.1101/2022.01.23.22269723
A1 Kentaro Tojo
A1 Natsuhiro Yamamoto
A1 Nao Tamada
A1 Takahiro Mihara
A1 Miyo Abe
A1 Mototsugu Nishii
A1 Ichiro Takeuchi
A1 Takahisa Goto
YR 2022
UL http://medrxiv.org/content/early/2022/11/18/2022.01.23.22269723.abstract
AB Acute respiratory distress syndrome (ARDS) with COVID-19 is aggravated by hyperinflammatory responses even after the peak of viral load has passed; however, its underlying mechanisms remain unclear. In the present study, analysis of the alveolar tissue injury markers and epithelial cell death markers in patients with COVID-19 revealed that COVID-19-induced ARDS was characterized by alveolar epithelial necrosis at an early disease stage. Serum levels of HMGB-1, one of DAMPs released from necrotic cells, were also significantly elevated in these patients. Further analysis using mouse model mimicking COVID-19-induced ARDS showed that the alveolar epithelial cell necrosis involved two forms of programmed necrosis, namely necroptosis and pyroptosis. Finally, the neutralization of HMGB-1 attenuated alveolar tissue injury in the mouse model. Collectively, necrosis, including necroptosis and pyroptosis, is the predominant form of alveolar epithelial cell death at an early disease stage and subsequent release of DAMPs is a potential driver of COVID-19-induced ARDS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly supported by AMED under Grant Number JP20he0522001, Yokohama Foundation for Advancement of Medical Science under Research Grant for COVID-19, JSPS KAKENHI Grant Number 21K16575 and 22K09146, and Grant for 2020-2021 Research Development Fund of Yokohama City University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yokohama City University Hospital institutional review boardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.